Back to results
US 2023/0405079 A1Published application
Lisinopril formulations
AssigneeAzurity Pharmaceuticals, Inc.
InventorsGerold L. MOSHER, David W. MILES
Life of this patent
Estimating the term…
Abstract
Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
Claims20
A stable oral liquid formulation, comprising:
- (i) about 1 mg/ml lisinopril or a pharmaceutically acceptable salt or solvate thereof;
- (ii) a preservative;
- (iii) a liquid vehicle, wherein the liquid vehicle comprises water;
- and
- (iv) a sweetener, wherein the sweetener comprises xylitol, mannitol, sorbitol, glycerin, maltitol, sucrose, aspartame, sucralose, saccharin, acesulfame, or a pharmaceutically acceptable salt thereof;
- wherein the pH of the formulation is between about 4 and about 8;
- wherein the formulation is stable at about 25±5° C. for at least 6 months.
4 more elements
A stable oral liquid formulation, comprising:
- (i) about 1 mg/ml lisinopril or a pharmaceutically acceptable salt or solvate thereof;
- (ii) a preservative;
- (iii) a liquid vehicle, wherein the liquid vehicle comprises water;
- (iv) a sweetener, wherein the sweetener comprises xylitol, mannitol, sorbitol, glycerin, maltitol, sucrose, aspartame sucralose, saccharin, acesulfame, or a pharmaceutically acceptable salt thereof;
- and
- (v) a buffer;
- wherein the formulation is stable at about 25±5° C. for at least 6 months.
4 more elements
Dependencies are inferred from the claim text.